Legal
Latest Bing Center News
WM and COVID-19: WMUK Webinar Recordings
On Friday 19 June, over 260 people joined our webinar, in partnership with Lymphoma Action, to hear our panel of UK experts answer some of the most commonly asked questions around COVID-19 and Waldenstrom's macroglobulinaemia (WM).
Ixazomib Plus Rituximab and Dexamethasone Safe, Effective for WM
Ixazomib in combination with subcutaneous rituximab and dexamethasone is feasible and shows promising efficacy and manageable toxicity in patients with relapsed WM.
BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. and BEIJING, China, June 18, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application ...
COVID-19 & Hematologic Malignancies: Patient Experience Update
We are excited to announce this new webcast focusing on the experience of patients undergoing treatment for hematologic malignancies during the COVID-19 era.
Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.
BTK Inhibitors for the Treatment of Waldenström Macroglobulinemia
In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.
ASCO 2020 Virtual Meeting
ASCO (American Society of Clinical Oncologists) will hold their 2020 conference online. As in the past, they provide abstracts online via the conference website. The scientific program will take place May 29 through May 31.
Video from CBS-4 Boston - Dr. Treon discusses COVID-19 / Ibrutinib Trial
Researchers say ibrutinib seems to protect those with COVID-19 from lung damage and respiratory distress. They will now conduct a trial to see if the medication can reduce a patient’s need for a ventilator, improve survival and reduce their time in the hospital.
COVID-19 Information for Our Patients
The Bing Center would like to share this important information with all of our patients and interested parties to help us all manage through this unprecedented crisis in the best and most productive way possible.
Waldenström Macroglobulinemia Specialty Channel
Welcome to the Oncology Learning Network Waldenstrom Macroglobulinemia Specialty Channel. Here you will find articles dedicated to the research and treatment of WM.